202 related articles for article (PubMed ID: 37516008)
1. Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.
Nagasaka M; Brazel D; Baca Y; Xiu J; Al-Hallak MN; Kim C; Nieva J; Swensen JJ; Spetzler D; Korn WM; Socinski MA; Raez LE; Halmos B; Ou SI
Transl Oncol; 2023 Oct; 36():101744. PubMed ID: 37516008
[TBL] [Abstract][Full Text] [Related]
2. A Performance Comparison of Commonly Used Assays to Detect RET Fusions.
Yang SR; Aypar U; Rosen EY; Mata DA; Benayed R; Mullaney K; Jayakumaran G; Zhang Y; Frosina D; Drilon A; Ladanyi M; Jungbluth AA; Rekhtman N; Hechtman JF
Clin Cancer Res; 2021 Mar; 27(5):1316-1328. PubMed ID: 33272981
[TBL] [Abstract][Full Text] [Related]
3. Pan-tumor survey of ROS1 fusions detected by next-generation RNA and whole transcriptome sequencing.
Nagasaka M; Zhang SS; Baca Y; Xiu J; Nieva J; Vanderwalde A; Swensen JJ; Spetzler D; Korn WM; Raez LE; Liu SV; Ou SI
BMC Cancer; 2023 Oct; 23(1):1000. PubMed ID: 37853341
[TBL] [Abstract][Full Text] [Related]
4. Identification of RET fusions in a Chinese multicancer retrospective analysis by next-generation sequencing.
Shi M; Wang W; Zhang J; Li B; Lv D; Wang D; Wang S; Cheng D; Ma T
Cancer Sci; 2022 Jan; 113(1):308-318. PubMed ID: 34710947
[TBL] [Abstract][Full Text] [Related]
5. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
6. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
[TBL] [Abstract][Full Text] [Related]
7. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
[TBL] [Abstract][Full Text] [Related]
8. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Subbiah V; Cassier PA; Siena S; Garralda E; Paz-Ares L; Garrido P; Nadal E; Vuky J; Lopes G; Kalemkerian GP; Bowles DW; Seetharam M; Chang J; Zhang H; Green J; Zalutskaya A; Schuler M; Fan Y; Curigliano G
Nat Med; 2022 Aug; 28(8):1640-1645. PubMed ID: 35962206
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.
Lin JJ; Liu SV; McCoach CE; Zhu VW; Tan AC; Yoda S; Peterson J; Do A; Prutisto-Chang K; Dagogo-Jack I; Sequist LV; Wirth LJ; Lennerz JK; Hata AN; Mino-Kenudson M; Nardi V; Ou SI; Tan DS; Gainor JF
Ann Oncol; 2020 Dec; 31(12):1725-1733. PubMed ID: 33007380
[TBL] [Abstract][Full Text] [Related]
10.
Arai S; Kita K; Tanimoto A; Takeuchi S; Fukuda K; Sato H; Yano S
Oncotarget; 2017 Sep; 8(43):73766-73773. PubMed ID: 29088743
[TBL] [Abstract][Full Text] [Related]
11. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract][Full Text] [Related]
12. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
[TBL] [Abstract][Full Text] [Related]
13. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent CCDC6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report.
Gu L; Ji W; Xu Y; Han Y; Jian H
Medicine (Baltimore); 2022 Nov; 101(47):e31480. PubMed ID: 36451418
[TBL] [Abstract][Full Text] [Related]
14. Pralsetinib for the treatment of a
Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics and diagnostic methods of
Feng J; Li Y; Wei B; Guo L; Li W; Xia Q; Zhao C; Zheng J; Zhao J; Sun R; Guo Y; Brcic L; Hakozaki T; Ying J; Ma J
Transl Lung Cancer Res; 2022 Apr; 11(4):617-631. PubMed ID: 35529790
[TBL] [Abstract][Full Text] [Related]
16. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
17. NCOA4-RET and TRIM27-RET Are Characteristic Gene Fusions in Salivary Intraductal Carcinoma, Including Invasive and Metastatic Tumors: Is "Intraductal" Correct?
Skálová A; Ptáková N; Santana T; Agaimy A; Ihrler S; Uro-Coste E; Thompson LDR; Bishop JA; Baněčkova M; Rupp NJ; Morbini P; de Sanctis S; Schiavo-Lena M; Vanecek T; Michal M; Leivo I
Am J Surg Pathol; 2019 Oct; 43(10):1303-1313. PubMed ID: 31162284
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
[TBL] [Abstract][Full Text] [Related]
19. Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A; Russo GL; Passiglia F; D'Arcangelo M; Sbrana A; Russano M; Bonanno L; Giusti R; Metro G; Bertolini F; Grisanti S; Carta A; Cecere F; Montrone M; Massa G; Perrone F; Simionato F; Guaitoli G; Scotti V; Genova C; Lugini A; Bonomi L; Attili I; de Marinis F
Lung Cancer; 2022 Dec; 174():118-124. PubMed ID: 36379124
[TBL] [Abstract][Full Text] [Related]
20. Catalog of 5' fusion partners in
Ou SI; Zhu VW
JTO Clin Res Rep; 2020 Jun; 1(2):100037. PubMed ID: 34589933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
